Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, JapanCorrespondence: Maiko Maruyama-InoueDepartment of Ophthalmology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Ka...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	ranibizumab aflibercept retinal angiomatous proliferation age-related macular degeneration intravitreal injection Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a86303419e6a445ba6f68caf68b45e2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a86303419e6a445ba6f68caf68b45e2b
record_format	dspace
spelling	oai:doaj.org-article:a86303419e6a445ba6f68caf68b45e2b2021-12-02T09:10:45ZPredictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation1177-5483https://doaj.org/article/a86303419e6a445ba6f68caf68b45e2b2019-10-01T00:00:00Zhttps://www.dovepress.com/predictive-factors-and-long-term-visual-outcomes-after-anti-vascular-e-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, JapanCorrespondence: Maiko Maruyama-InoueDepartment of Ophthalmology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanTel +81 45 261 5656Fax +81 45 253 8490Email maicoo@urahp.yokohama-cu.ac.jpPurpose: To report the results of 9-year follow-up examinations and predictive factors for visual acuity outcome after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents to treat retinal angiomatous proliferation (RAP).Methods: We conducted a retrospective observational study of 85 treatment-naïve eyes in 61 patients (21 men, 40 women; age range, 70–95 years; mean age, 84.0 years) treated with intravitreal injections of anti-VEGF agents. All patients received three consecutive monthly injections as an induction treatment. During the maintenance phase, the patients received intravitreal injections as needed or fixed dosing. The primary outcome measures were best-corrected visual acuity (BCVA) during the follow-up period. Furthermore, we investigated potential predictive factors of improvement in visual acuity. The proportion of patients who developed specific complications were also analyzed.Results: The mean BCVA gradually decreased from 0.58 at baseline to 0.70 at 36 months (P = 0.146), 0.82 at 48 months (P = 0.004), and 0.92 at 108 months (P = 0.021). Improvement in visual acuity at the final visits was associated with baseline visual acuity and central foveal thickness. Massive subretinal hemorrhage, fibrotic scars, and macular atrophy developed in 4 (4.7%), 9 (10.6%), and 50 (56.8%) eyes, respectively, at the final visits, and were all significantly associated with final visual acuity (P = 0.013, P < 0.001, and P = 0.001, respectively).Conclusion: Long-term stabilization of vision in patients with RAP, regardless of treatment modality, was difficult to achieve by using intravitreal injections of anti-VEGF agents. Earlier detection and treatment are important to maintain visual acuity in patients with RAP.Keywords: ranibizumab, aflibercept, retinal angiomatous proliferation, age-related macular degeneration, intravitreal injection  Maruyama-Inoue MSato SYamane SKadonosono KDove Medical Pressarticleranibizumabafliberceptretinal angiomatous proliferationage-related macular degenerationintravitreal injectionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1981-1989 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	ranibizumab aflibercept retinal angiomatous proliferation age-related macular degeneration intravitreal injection Ophthalmology RE1-994
spellingShingle	ranibizumab aflibercept retinal angiomatous proliferation age-related macular degeneration intravitreal injection Ophthalmology RE1-994 Maruyama-Inoue M Sato S Yamane S Kadonosono K Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
description	Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, JapanCorrespondence: Maiko Maruyama-InoueDepartment of Ophthalmology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa 232-0024, JapanTel +81 45 261 5656Fax +81 45 253 8490Email maicoo@urahp.yokohama-cu.ac.jpPurpose: To report the results of 9-year follow-up examinations and predictive factors for visual acuity outcome after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents to treat retinal angiomatous proliferation (RAP).Methods: We conducted a retrospective observational study of 85 treatment-naïve eyes in 61 patients (21 men, 40 women; age range, 70–95 years; mean age, 84.0 years) treated with intravitreal injections of anti-VEGF agents. All patients received three consecutive monthly injections as an induction treatment. During the maintenance phase, the patients received intravitreal injections as needed or fixed dosing. The primary outcome measures were best-corrected visual acuity (BCVA) during the follow-up period. Furthermore, we investigated potential predictive factors of improvement in visual acuity. The proportion of patients who developed specific complications were also analyzed.Results: The mean BCVA gradually decreased from 0.58 at baseline to 0.70 at 36 months (P = 0.146), 0.82 at 48 months (P = 0.004), and 0.92 at 108 months (P = 0.021). Improvement in visual acuity at the final visits was associated with baseline visual acuity and central foveal thickness. Massive subretinal hemorrhage, fibrotic scars, and macular atrophy developed in 4 (4.7%), 9 (10.6%), and 50 (56.8%) eyes, respectively, at the final visits, and were all significantly associated with final visual acuity (P = 0.013, P < 0.001, and P = 0.001, respectively).Conclusion: Long-term stabilization of vision in patients with RAP, regardless of treatment modality, was difficult to achieve by using intravitreal injections of anti-VEGF agents. Earlier detection and treatment are important to maintain visual acuity in patients with RAP.Keywords: ranibizumab, aflibercept, retinal angiomatous proliferation, age-related macular degeneration, intravitreal injection
format	article
author	Maruyama-Inoue M Sato S Yamane S Kadonosono K
author_facet	Maruyama-Inoue M Sato S Yamane S Kadonosono K
author_sort	Maruyama-Inoue M
title	Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
title_short	Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
title_full	Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
title_fullStr	Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
title_full_unstemmed	Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
title_sort	predictive factors and long-term visual outcomes after anti-vascular endothelial growth factor treatment of retinal angiomatous proliferation
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/a86303419e6a445ba6f68caf68b45e2b
work_keys_str_mv	AT maruyamainouem predictivefactorsandlongtermvisualoutcomesafterantivascularendothelialgrowthfactortreatmentofretinalangiomatousproliferation AT satos predictivefactorsandlongtermvisualoutcomesafterantivascularendothelialgrowthfactortreatmentofretinalangiomatousproliferation AT yamanes predictivefactorsandlongtermvisualoutcomesafterantivascularendothelialgrowthfactortreatmentofretinalangiomatousproliferation AT kadonosonok predictivefactorsandlongtermvisualoutcomesafterantivascularendothelialgrowthfactortreatmentofretinalangiomatousproliferation
_version_	1718398202841923584

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

Ejemplares similares